



BRAF V600E Mutations are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

Citation

Dias-Santagata, Dora, Quynh Lam, Kathy Vernovsky, Natalie Vena, Jochen K. Lennerz, Darrell R. Borger, Tracy T. Batchelor, et al. 2011. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: Diagnostic and therapeutic implications. PLoS ONE 6(3): e17948.

Published Version

doi:10.1371/journal.pone.0017948

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:8461944>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications

Dora Dias-Santagata¹, Quynh Lam¹, Kathy Vernovsky², Natalie Vena^{3,4}, Jochen K. Lennerz¹, Darrell R. Borger², Tracy T. Batchelor^{2,5}, Keith L. Ligon^{3,4,6,7}, A. John Iafrate¹, Azra H. Ligon^{4,7}, David N. Louis¹, Sandro Santagata^{6,7*}

1 Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, **2** Division of Hematology-Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, United States of America, **3** Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, **4** Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, **5** Department of Neurology and Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America, **6** Department of Pathology, Children's Hospital Boston and Harvard Medical School, Boston, Massachusetts, United States of America, **7** Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

Abstract

Pleomorphic xanthoastrocytoma (PXA) is low-grade glial neoplasm principally affecting children and young adults. Approximately 40% of PXA are reported to recur within 10 years of primary resection. Upon recurrence, patients receive radiation therapy and conventional chemotherapeutics designed for high-grade gliomas. Genetic changes that can be targeted by selective therapeutics have not been extensively evaluated in PXA and ancillary diagnostic tests to help discriminate PXA from other pleomorphic and often more aggressive astrocytic malignancies are limited. In this study, we apply the SNaPshot multiplexed targeted sequencing platform in the analysis of brain tumors to interrogate 60 genetic loci that are frequently mutated in 15 cancer genes. In our analysis we detect BRAF V600E mutations in 12 of 20 (60%) WHO grade II PXA, in 1 of 6 (17%) PXA with anaplasia and in 1 glioblastoma arising in a PXA. Phospho-ERK was detected in all tumors independent of the BRAF mutation status. BRAF duplication was not detected in any of the PXA cases. BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM (gcGBM). The finding that BRAF V600E mutations are common in the majority of PXA has important therapeutic implications and may help in differentiating less aggressive PXAs from lethal gcGBMs and GBMs.

Citation: Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, et al. (2011) BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE 6(3): e17948. doi:10.1371/journal.pone.0017948

Editor: Iris Schrijver, Stanford University School of Medicine, United States of America

Received: December 20, 2010; **Accepted:** February 16, 2011; **Published:** March 29, 2011

Copyright: © 2011 Dias-Santagata et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Aid for Cancer Research Foundation and from an anonymous donor (to MGH) and the PLGA Foundation. KLL is supported by National Institutes of Health (NIH) grant CA095616, the Sontag Foundation, and the Goldhirsh Foundation. DNL is supported by NIH grant CA57683. SS is supported by NIH grant K08NS064168, the V Foundation for Cancer Research and the Brain Science Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: DDS and AJI submitted a patent application for the SNaPshot genotyping methods used in this study. DDS, AJI and DRB have been consultants for Bio-Reference Laboratories, Inc.

* E-mail: ssantagata@partners.org

Introduction

Pleomorphic xanthoastrocytoma (PXA) is an uncommon low-grade glial neoplasm of the central nervous system that most frequently affects children and young adults [1–6]. The tumors often arise in the temporal lobe and involve both the superficial cortex and the overlying meninges [7–9]. During the clinical evaluation of PXA resection specimens, the dense cellularity and pleomorphism typical of PXA raises a differential diagnosis including ganglioglioma and a range of high-grade malignancies like glioblastoma (GBM), giant cell glioblastoma (gcGBM), gliosarcoma or pleomorphic sarcoma [1,5]. The presence of eosinophilic granular bodies and the compact, predominantly non-infiltrating nature of PXA also can introduce pilocytic astrocytoma into the differential diagnosis [5]. The histopathologic diagnosis of PXA can often be accomplished readily when the histologic

findings are carefully considered in light of the clinical and radiological features, although the diagnosis can be challenging and confusion with other neoplasms can occur [10]. A reproducible ancillary diagnostic marker for PXA would, therefore, be of significant clinical use.

PXA are typically slow growing at presentation and as a result patients commonly experience long-standing seizures. While the prognosis is relatively favorable, the recurrence rate following resection is 30% within five years and about 40% within ten years. The overall survival rate is 80% at five years and 70% at ten years [9,11]. In its classic form, the histology of the tumors is distinct with large pleomorphic giant cells demonstrating xanthomatous change, a dense deposition of intercellular reticulin and the presence of eosinophilic granular bodies [12]. Anaplastic changes such as high mitotic activity and necrosis are uncommon at initial presentation but become

Table 1. SNaPshot tumor genotyping panel.

Gene	Amino acid - cDNA residue	Gene	Amino acid - cDNA residue
APC	R1114 - 3340C	KRAS	G12 - 34G
APC	Q1338 - 4012C	KRAS	G12 - 35G
APC	R1450 - 4348C	KRAS	G13 - 37G
APC	T1556fs* - 4666_4667insA	KRAS	G13 - 38G
BRAF	V600 - 1798G	NOTCH1	L1575 - 4724T
BRAF	V600 - 1799T	NOTCH1	L1601 - 4802T
CTNNB1	D32 - 94G	NRAS	G12 - 34G
CTNNB1	D32 - 95A	NRAS	G12 - 35G
CTNNB1	S33 - 98C	NRAS	G13 - 37G
CTNNB1	G34 - 101G	NRAS	G13 - 38G
CTNNB1	S37 - 109T	NRAS	Q61 - 181C
CTNNB1	S37 - 110C	NRAS	Q61 - 182A
CTNNB1	T41 - 121A	NRAS	Q61 - 183A
CTNNB1	T41 - 122C	PIK3CA	R88 - 263G
CTNNB1	S45 - 133T	PIK3CA	E542 - 1624G
CTNNB1	S45 - 134C	PIK3CA	E545 - 1633G
EGFR	G719 - 2155G	PIK3CA	Q546 - 1636C
EGFR	T790 - 2369C	PIK3CA	Q546 - 1637A
EGFR	L858 - 2573T	PIK3CA	H1047 - 3139C
EGFR	E746_A750 - 2235_2249del	PIK3CA	H1047 - 3140A
EGFR	E746_A750 - 2236_2250del	PIK3CA	G1049 - 3145G
FLT3	D835 - 2503G	PTEN	R130 - 388C
IDH1	R132 - 394C	PTEN	R173 - 517C
IDH1	R132 - 395G	PTEN	R233 - 697C
IDH2	R172 - 514A	PTEN	K267fs* - 800delA
IDH2	R172 - 515G	TP53	R175 - 524G
JAK2	V617 - 1849G	TP53	G245 - 733G
KIT	D816 - 2447A	TP53	R248 - 742C
		TP53	R248 - 743G
		TP53	R273 - 817C
		TP53	R273 - 818G
		TP53	R306 - 916C

The panel tests 60 frequently mutated loci in 15 cancer genes. Because several nucleotide variants have been described at each site, this assay can detect 140 previously described mutations according to the COSMIC database, v49 release (<http://www.sanger.ac.uk/genetics/CGP/cosmic/>). doi:10.1371/journal.pone.0017948.t001

Slide Preparation, Immunohistochemistry, Histology Staining and Scoring

Clinical specimens that had been fixed in 10% buffered-formalin and prepared as FFPE tissue blocks were used to generate four-micron sections. The slides were stained with H&E. Serial sections of the paraffin blocks were cut and these slides were used for immunohistochemistry (IHC) as well as mutation analysis. For IHC, tissue sections were deparaffinized and rehydrated through xylene/graded alcohols. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide (15 min incubation) in 100% alcohol (1:1). Heat-induced antigen retrieval was carried out with Dako Target Retrieval Solution, pH 6.0, and pressure cooker

heated (120+/-2°C) for 30 seconds at 15+/-5 psi. Sections were stained for phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) using a 1:500 dilution of rabbit monoclonal antibody (#4370: Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) from Cell Signaling Technology (Beverly, MA). The antibody was optimized using SignalSlide™ Phospho-p44/42 MAPK (Thr202/Tyr204) IHC Controls from Cell Signaling (#8103) that consist of paraffin-embedded NIH/3T3 cells that are either untreated or PMA-treated. The antibody is reported to detect endogenous levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when phosphorylated at residues Thr202 and Tyr204 of Erk1 and (Thr185 and Tyr187 of Erk2), and singly phosphorylated at Thr202. The antibody is reported not to cross-react with the corresponding phosphorylated residues of either p38 MAP or JNK/SAPK kinases. Application of the primary antibodies was followed by a 30-minute incubation with Dako Labeled Polymer-HRP anti-rabbit IgG secondary antibody, and visualized with 3, 3'-diaminobenzidine (DAB) as a chromogen (Envision+ System) with Mayer hematoxylin counterstaining. Grading of phospho-p44/42 MAPK immunoreactivity was based on the following semiquantitative approach: 0, no tumor cells demonstrating staining; 1+, >0-25% of tumor cells reactive; 2+, >25%-50% of tumor cells reactive; 3+, >50%-75% of tumor cells reactive; 4+, >75% of cells reactive. Giant cell glioblastoma sections were stained with a monoclonal antibody directed against p53 (clone DO-1, Immunotech, Marseille, France) at a 1:1200 dilution using similar conditions as described above for the phospho-p44/42 MAPK (Erk1/2). Reticulin staining was performed with Reticulin/Nuclear Fast Red Stain Kit, Artisan™ (DAKO, Carpinteria, CA), according to the manufacturer's recommendations.

Fluorescence In Situ Hybridization

Fluorescence *in situ* hybridization (FISH) was performed on four micron tissue sections using the D7Z1 DNA Probe (chromosome 7 alpha satellite DNA) (Abbott Molecular) at 7p11.1-q11.1 and homebrew probes (purchased from CHORI; www.chori.org) RP11-767F15 and RP11-60F17 that map to 7q34. The RP11-767F15 probe includes the 5' region of *BRAF* and the RP11-60F17 probe includes the 3' region of *BRAF*. *BRAF* duplication status was assessed in 50 tumor nuclei per case.

Statistical Analysis

Statistical Analysis consisted of Fisher's exact test (association of dichotomous factors), or t-test (comparison of means). Data analysis was conducted using Prism 5.0b (GraphPad Software Inc., San Diego, CA) and significance was defined as P<0.05.

Results

Glioma Cases Profiled with SNaPshot

To investigate the genetic changes underlying pleomorphic xanthoastrocytomas, we identified relevant tumors that were resected between 1996 and 2010 at Massachusetts General Hospital, Brigham and Women's Hospital, and Children's Hospital Boston. We retrieved cases that were thought to be unequivocal grade II PXA during the clinical evaluation of the surgical pathology specimens as well as tumors that demonstrated most of the features of PXA and were thought to be "consistent with PXA." In addition, we identified cases of PXA with anaplastic features (aPXA) such as necrosis and increased mitoses as well as cases of giant cell glioblastoma (gcGBM, grade IV). Representative images are illustrated in Figure 1. In all, we retrieved 36 resection specimens of astrocytomas with marked cellular pleomorphism from 35 patients, with one patient having

both a primary (BT29) PXA resected and then a recurrence of a PXA with anaplastic features (BT 41). Thirty of the cases were primary tumors and six were recurrences. Five of the six recurrences had primary resections performed at an outside hospital and the primary surgical specimen was not available for genotyping. In total, we analyzed 20 cases of grade II PXA and six cases of aPXA, (Table 2). We also analyzed nine gcGBM since this variant of glioblastoma is commonly included in the differential diagnosis of PXA. The age distribution of patients with grade II PXAs was 7 years to 71.5 years with mean and median ages at

presentation of 25.8 years and 19.1 years, respectively. The age distribution of patients at the time of aPXA resection was 29.3 years to 76.2 years with mean and median ages at presentation of 57.4 years and 54.3 years, respectively. The grade II PXAs histologically fell into two general types: those that had predominantly a distinct mesenchymal-like growth pattern with fascicular and sometimes storiform growth pattern (PXA (m)) (Fig. 1A and B) and those that predominantly had a diffuse fibrillary background (Fig. 1C and D). PXA (m) tumors were more likely to demonstrate intercellular reticulin deposition. Interest-

Table 2. Clinical Data and Summary of Results.

Case #	Hospital	Gender	Age (yrs)	Size (cm)	Side	Location	Histology Classification	SNaPshot Result	BRAF FISH	pERK	Reticulin	Specimen Genotyped
BT06	CH	F	7.0	3.4	Right	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	No duplication	1	Present	Recurrence
BT07	CH	F	10.9	2.2	Left	Temporal	PXA	No mutations	No duplication	3	Absent	Primary
BT19	MGH	M	15.3	1	Right	Temporal	PXA (m)	No mutations	NA	4	Present	Primary
BT20	MGH	M	42.8	0.8	Left	Occipital	PXA*	BRAF V600E (c.1799T>A)	NA	4	Present	Primary
BT21	MGH	M	19.7	0.9	Left	Temporal	PXA	BRAF V600E (c.1799T>A)	No duplication	3	Focal	Primary
BT22	MGH	M	43.5	6.8	Left	Frontal	aPXA	BRAF V600E (c.1799T>A)	No duplication	4	Focal	Recurrence
BT23	MGH	F	47.1	1.2	Right	Suprasellar	PXA	No mutations	No duplication	2	Present	Primary
BT24	MGH	F	12.0	2.6	Right	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	NA	4	Present	Primary
BT25	BWH	F	10.2	1.5	Left	Frontal	PXA	No mutations	No duplication	4	Present	Primary
BT26	BWH	M	71.5	2	Right	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	No duplication	2	Present	Primary
BT27	BWH	M	37.9	6	Right	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	No duplication	1	Present	Primary
BT28	BWH	M	18.8	NA	Right	Parietal	PXA	No mutations	No duplication	2	Focal	Recurrence
BT29	BWH	M	45.7	0.6	Right	Temporal	PXA	No mutations	No duplication	4	Focal	Primary
BT30	BWH	M	29.3	3	Right	Frontal	aPXA	No mutations	No duplication	4	Present	Primary
BT31	BWH	M	29.1	NA	Left	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	No duplication	3	Present	Recurrence
BT35	MGH	M	24.5	1.9	Right	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	NA	3	Present	Primary
BT36	MGH	F	76.2	5	Right	Parietal	aPXA	No mutations	NA	3	Focal	Primary
BT38	CH	F	18.7	1.2	Right	Frontal	PXA	BRAF V600E (c.1799T>A)	NA	2	Focal	Recurrence
BT39	BWH	M	18.6	2.4	Left	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	No duplication	3	Focal	Primary
BT41	BWH	M	46.6	1.1	Right	Temporal	aPXA	No mutations	No duplication	4	Focal	Recurrence
BT44	BWH	M	86.8	NA	Left	Temporal	aPXA	No mutations	NA	4	Absent	Primary
BT46	CH	F	19.3	3.8	Left	Parietal/ Occipital	PXA	No mutations	No duplication	4	Present	Primary
BT47	CH	M	16.5	NA	Right	Temporal	PXA (m)	BRAF V600E (c.1799T>A)	NA	1	Present	Primary
BT48	CH	F	16.3	1	Right	Temporal	PXA	BRAF V600E (c.1799T>A)	No duplication	2	Present	Primary
BT49	BWH	F	30.7	2.1	Left	Temporal	gcGBM arising in PXA	BRAF V600E (c.1799T>A)	NA	4	Focal	Primary
BT52	MGH	F	33.4	4	Right	Temporal	PXA	No mutations	NA	2	Focal	Primary
BT56	BWH	F	62.1	4.6	Right	Frontal	aPXA	No mutations	No duplication	4	Focal	Primary

PXA – pleomorphic xanthoastrocytoma; PXA (m) – pleomorphic xanthoastrocytoma with mesenchymal-like growth pattern; aPXA – anaplastic pleomorphic xanthoastrocytoma; NA – Not assessed.

doi:10.1371/journal.pone.0017948.t002




Figure 1. Representative photomicrographs of tumors. A. H&E-stained section of a pleomorphic xanthoastrocytoma (PXA, BT06) demonstrating fascicular growth pattern and prominent intercellular reticulin deposition (B) corresponding to PXA (m). C. H&E-stained section of PXA (BT21) that demonstrates neither a fascicular growth pattern nor prominent intercellular reticulin deposition (D). E. H&E-stained section of a giant cell glioblastoma (gcGBM) arising from a PXA (BT49) with marked pleomorphism and giant cells and multifocal reticulin deposition (F).

doi:10.1371/journal.pone.0017948.g001

ingly, all nine of the PXAs with prominent mesenchymal-like growth originated in the temporal lobe. In contrast, only five of the remaining 11 PXA cases (45%) were found in the temporal lobe, with others located in frontal lobe ($n=2$), suprasellar region ($n=1$), and in the parietal/occipital lobes ($n=3$). The mean age for grade II PXA with prominent mesenchymal-like growth was 25.8 years, whereas the remaining grade II PXAs had a mean age of 25.7 years.

SNaPshot Analysis Reveals that BRAF V600E Mutations are Common in PXA

To characterize DNA mutations in this group of PXA tumors we performed SNaPshot multiplexed genotyping (Figure 2). The genotyping analysis queried 60 commonly mutated loci in 15 cancer genes (Table 1) testing for 140 previously described somatic mutations (COSMIC database, v49 release). The BRAF V600E mutation was identified in 12 of the 20 PXA (60%). The average age of patients bearing the BRAF V600E-positive PXA was 26.2 years versus 25.1 years in those without the mutation. The average tumor size at presentation for BRAF V600E-positive tumors was 2.2 cm compared to 2.0 cm for BRAF V600E-negative tumors. In our cohort of 11 males and nine females with a PXA, 73% of males with PXA (8 of 11) had a BRAF V600E mutation while only 44% of females with PXA (4 of 9) had a BRAF V600E mutation. Despite BRAF V600E-positive PXA occurring more frequently in males in our cohort, the association between tumor mutational

status and gender was not significant (p value 0.36). Interestingly, the mutation was present in 8 of 9 PXA demonstrating prominent mesenchymal-like growth pattern (PXA (m)), revealing a significant association of BRAF V600E mutation with PXA (m) (p value 0.028). Of the remaining four BRAF V600E-positive PXA cases, two were also present in the temporal lobe, one was present in the frontal lobe and the remaining one originated in the occipital lobe and displayed ganglion cell/neuronal differentiation (BT20). In all, 70% of the PXA originated in the temporal lobe and 83.3% of the BRAF V600E-positive grade II PXAs were located in the temporal lobe. Given the cohort size and the limited availability of follow up data, correlative analysis regarding the prognostic significance of the BRAF V600E mutation was not possible in grade II PXAs. The BRAF V600E mutation was present in only one of the six aPXA, in the single gcGBM arising from a PXA in our cohort and in one of nine additional gcGBM (11%). The aPXA case bearing a BRAF V600E mutation was a recurrence of a grade II PXA and was located in the frontal lobe. The primary tumor for this recurrence was not available for genotyping. The BRAF V600E-positive gcGBM arising in a PXA was also located in the temporal lobe. Neither of these two gcGBM specimens had amplification of the *EGFR* locus.

BRAF V600E mutation has not been previously reported in gcGBM but it has been reported to occur at low frequency in glioblastoma and in one case of gliosarcoma. In total, BRAF V600E mutation in standard glioblastomas has been reported in approximately 1.7% of cases (5 of nearly 300 cases) [25–29]. In line with this mutation frequency, review of 62 standard glioblastoma cases that had undergone clinical testing at MGH using SNaPshot mutation profiling identified only one case with a BRAF V600E mutation (1.6%). Of note, SNaPshot clinical testing of these 62 GBMs included the assays depicted in Table 1 except for *IDH2*. Review of these GBM cases also revealed additional low frequency mutations in cancer genes that have been previously described to be altered in standard GBM (Table 3) including mutations in *IDH1* (3; 4.8%), *KRAS* (1; 1.6%), *PIK3CA* (4; 6.5%), and *TP53* (7; 11.3%) supporting the strength of using multiplexed tumor genotyping to identify low frequency mutations, some of which can be treated with targeted therapeutics. Also highlighting the strengths of a multiplexed genotyping approach is the observation that one of the mutations identified in *IDH1* (c.394C>T) results in a R132C substitution that would not be identified by IHC using an *IDH1* R132H mutation specific antibody.

One *TP53* mutation (p.R248Q; c.743G>A) was found in a gcGBM tumor sample but additional mutations profiled by the SNaPshot system were absent in these gcGBM cases. Mutations in the *TP53* gene have been reported in 60–90% of gcGBM cases [30–32]. Since the SNaPshot panels used in our experiments cover less than 30% of the *TP53* mutations that have been reported in gcGBM (COSMIC database, v49 release), the odds dictate that we would have detected a *TP53* mutation in about 2 of the 9 cases in this study. Support for the existence of *TP53* mutations in many of the gcGBMs analyzed in this study was provided by p53 immunohistochemistry which revealed increased p53 expression in 7 of the 9 (78%) gcGBM.

Interestingly, none of the other mutations in the SNaPshot panel that are commonly found in cancer were present in the PXAs that were analyzed including those described above for standard GBM. Of note, mutations at the most frequently affected amino acid residues in the isocitrate dehydrogenase genes 1 (*IDH1*, R132) and 2 (*IDH2*, R172) and *TP53* (R175, G245, R248, R273 and R306) were not identified in any of PXA samples. In all, this data shows the BRAF V600E mutation is common in PXA but is




Figure 2. Mutation profiling of pleomorphic xanthoastrocytoma and giant cell glioblastoma arising in a PXA reveals BRAF V600E mutations. The sections on the left illustrate SNaPshot genotyping and the sections on the right depict Sanger sequencing of *BRAF* exon 15 for the same samples. The top panel shows genotyping data obtained with normal male genomic DNA (Promega, Madison, WI). The lower panels illustrate BRAF V600E (c.1799T>A) mutation detection (arrows) in tumor DNA derived from formalin-fixed paraffin-embedded specimens of representative examples of: PXA (BT21), anaplastic PXA (BT22) and gcGBM arising in a PXA (BT49). Assays: (1) *EGFR* 2235_49del R; (2) *NRAS* 38; (3) *BRAF* 1799; (4) *NRAS* 182; (5) *PIK3CA* 263; (6) *TP53* 742; (7) *CTNNB1* 95 and (8) *CTNNB1* 122. doi:10.1371/journal.pone.0017948.g002

infrequent in much more aggressive tumors like GBM and gcGBM that enter the differential diagnosis of PXA.

Phospho-ERK Immunohistochemistry and BRAF FISH Analysis

To address the functional consequences of BRAF V600E mutations in PXA, we assessed MAPK pathway activation by measuring levels of phospho-p44/42 MAPK (Erk1/2) by IHC. While immunoblot analysis provides a quantitative method for assessing differences in phosphorylation, access to only FFPE and not frozen samples of this uncommon tumor permitted analysis by the less quantitative method of IHC. Staining was scored using a semiquantitative scoring system (0–4 scoring system). Interestingly, the BRAF V600E mutation in grade II PXA did not result in an overt increase in levels of phospho-ERK for mutated tumors (mean score 2.4 for BRAF V600E-positive Grade II PXA and 3.1 for BRAF V600E-negative Grade II PXA; p value 0.13). Representative images of staining are displayed in Figure 3.

Since *BRAF* duplication has been identified as a mechanism for activation of the MAPK pathway in pilocytic astrocytomas [33–38] we investigated copy number alterations at the *BRAF* locus by FISH. Results were obtained for seven of the 12 BRAF V600E-positive grade II PXA, for six of the eight BRAF V600E-negative grade II PXA and for three of the five aPXA lacking the BRAF V600E mutation. While some tumors showed polysomy of chromosome 7 (3–5 copies) in a portion of the tumor cells, none of the tumors analyzed by FISH showed *BRAF* duplication (Fig. 3G, H) suggesting that this mechanism does not account for the activation of the MAPK pathway observed in BRAF V600E-negative PXA.

Discussion

The BRAF V600E Mutation is Common in PXA

While BRAF V600E mutations have been described as a common mutation in ganglioglioma (GG) by both our group and others [16,39], the frequency of BRAF V600E mutation in other low-grade gliomas has not been investigated in depth. An individual case with BRAF V600E mutation has been reported for pilocytic astrocytoma [16] and several diffuse astrocytomas (WHO grade II) have also been




Figure 3. Phospho-ERK (pERK) immunostaining and fluorescence in situ hybridization (FISH) for BRAF. Validation of the pERK antibody using NIH/3T3 cells that are either untreated (A) or PMA-treated (B). C. pERK IHC of BT06 PXA with a BRAF V600E mutation (IHC semi-quantitative score 1). D. BT23 PXA without BRAF V600E mutation (IHC semi-quantitative score of 2). E. BT24 PXA with a BRAF V600E mutation (IHC semi-quantitative score 4). F. BT25 PXA without BRAF V600E mutation (IHC semi-quantitative score of 4). G. *BRAF* FISH with probes for CEP7 (centromeric control probe - aqua), 5' *BRAF* (green) and 3' *BRAF* (red). PXA BT29 demonstrating no duplication of the *BRAF* locus and chromosome 7 disomy. H. PXA BT41, which is the recurrence of BT29, did not have duplication of the *BRAF* locus but demonstrated chromosome 7 polysomy. doi:10.1371/journal.pone.0017948.g003

Table 3. Mutation analysis of GBM.

Gene	Mutation	No. of cases
<i>BRAF</i>	p.V600E, c.1799T>A	1
<i>IDH1</i>	p.R132C, c.394C>T	1
	p.R132H, c.395G>A	2
<i>KRAS</i>	p.G12A, c.35G>C	1
<i>PIK3CA</i>	p.R88Q, c.263G>A	3
	p.H1047R, c.3140A>G	1
<i>TP53</i>	p.R175H, c.524G>A	1
	p.R248W, c.742 C>T	2
	p.R273C, c.817C>T	2
	p.R273H, c.818G>A	1
	p.R306*(STOP), c.916C>T	1

SNaPshot clinical genotyping of 62 glioblastoma cases from MGH identified cancer gene mutations that confer a favorable prognosis to the patients (*IDH1*) or that activate pathways targeted by therapeutic agents under clinical development (*BRAF*, *KRAS* and *PIK3CA*). doi:10.1371/journal.pone.0017948.t003

identified with BRAF V600E mutation [16,39,40]. During the preparation of this manuscript, individual cases of WHO grade II PXA with BRAF V600E mutation have been reported with one occurring in the temporal lobe of a 36-year-old woman [39], one in the cerebral cortex of a six-year-old girl [41] and one in the temporal lobe of a 16 year old boy with velocardiofacial syndrome [42]. Notably, we now identify the BRAF V600E mutation in approximately 60% of grade II PXA, a similar mutation rate as seen in malignant melanoma [43]. Also of interest, is that a number of common mutations found in some classes of human glial tumors are absent in our PXA cohort, including mutations in *IDH1* and *IDH2* [24,44,45] and that *BRAF* is not duplicated in PXA. Also of note, during the review process of this manuscript, a separate study was published identifying BRAF V600E mutations in 66% of PXA [23], consistent with the findings in our study.

There is variability in the histopathologic presentation of PXA. Common features of PXA include xanthomatous change and marked cellular pleomorphism, however, some tumors demonstrate fascicular or storiform growth of spindle-type cells [1,7,46] while others are characterized by a diffuse, glial/fibrillary pattern of growth [1]. Nearly 50% of the tumors in our series displayed a mesenchymal-like growth pattern and were designated PXA (m) (Table 2). All of the PXA (m) tumors originated in the temporal lobe and interestingly, in our series, nearly all (89%) of these PXA (m) tumors harbored BRAF V600E mutations, whereas the mutation was only present in 36% of the remaining PXA. The gcGBM arising in a PXA which harbored a BRAF V600E mutation in our series also arose from a PXA demonstrating a mesenchymal-like growth pattern and was also located in the temporal lobe. Analysis of more PXA cases will be required to see whether the strong association holds between BRAF V600E mutation and PXA (m). Nonetheless, our data seems to support that the classification of PXA, as currently used, is molecularly heterogeneous and may be composed of a group of BRAF V600E-positive PXAs predominantly originating in the temporal lobe that display pleomorphic giant cells, xanthomatous change, and fascicular and storiform growth pattern. This group may be clinically and molecularly distinct from the remaining PXA tumors.

Diagnostic Considerations

The diagnosis of PXA is traditionally based on examination of H&E-stained sections and reticulin preparations as well as integration of clinical and radiological information [1,2,5]. The identification of BRAF V600E mutations as a common mutation in PXA offers an ancillary diagnostic tool that can help discriminate PXA from standard GBM and gcGBM as well as pilocytic astrocytoma. Since a similar percentage of ganglioglioma (GG) harbor BRAF V600E mutations (approximately 60%), the BRAF V600E status will not help to discriminate PXA and GG. While a more complete survey of other uncommon low-grade gliomas is still required, it appears likely that the high frequency of BRAF V600E mutations will be the hallmark of PXA and GG. Interestingly, in addition to the strong clinicopathologic similarities of PXA and GG, composite PXA-GG tumors are also observed, albeit infrequently [47,48]. One of the cases in our study (BT 20)

demonstrates such mixed features and was found to carry a BRAF V600E mutation. This molecular link between PXA and GG further supports the clinicopathologic overlap between these tumors and raises the possibility of a shared molecular pathogenesis/histogenesis.

Additional molecular tests can be used as part of a panel including BRAF V600E analysis in the evaluation of PXA. The absence of *BRAF* duplication in our PXA series can help distinguish PXA from the 40% of non-cerebellar PAs and 80% of cerebellar PAs [37] that have *BRAF* rearrangements. The absence of *IDH1* and *IDH2* mutations in our PXA cohort suggests that these mutations are rare or not present in PXA, a feature that can help discriminate PXA from the 87.5% of diffuse glioma that bear mutations in these gene [49]. Also, FISH or CISH for *EGFR* can be of assistance since *EGFR* is amplified in 30–40% of GBM [2]. The integrated molecular genetic evaluation of PXA can help facilitate appropriate histologic classification.

Therapeutic Considerations

The activation of the MAPK pathway in PXA has significant therapeutic implications as well. Moderate to high level expression of phospho-ERK was observed by IHC in the majority of PXA and aPXA suggesting that MAPK signaling is an important component of PXA. These findings suggest that PXA may be responsive to treatment with orally available BRAF kinase inhibitors such as PLX-4032 [50] as well as by HSP90 inhibitors which destabilize mutated BRAF [51,52]. BRAF V600E-positive melanomas seem to be highly dependent on activation of the MAPK pathway for proliferation and maintenance functions. Preclinical testing in melanoma has demonstrated that PLX-4032 can inhibit the *in vitro* and *in vivo* proliferation of BRAF V600E melanoma cell lines and clinical trials of PLX-4032 have shown clinical responses in BRAF V600E melanoma with the extent of response associated with the level of inhibition of phospho-ERK [50,53–55]. These studies have provided the proof-of-principle for the use of BRAF inhibitors in melanoma, and raise the possibility of using targeted small molecule therapeutics like PLX-4032 in the treatment of PXA and GG, particularly in the setting of recurrence or in cases where noncytotoxic chemotherapy can serve as an adjuvant treatment to permit resection of complex lesions [56]. Most critical now will be to demonstrate sensitivity of BRAF V600E-positive glioma cell lines and tumors to BRAF targeted therapeutics. In addition it will be important to identify and validate other pathways that contribute to the proliferation of PXA and GG. Such studies could provide the rationale for concurrently targeting additional pathways besides MAPK to generate clinical responses and sustained remissions.

Author Contributions

Conceived and designed the experiments: DDS SS. Performed the experiments: DDS QL KV NV AHL SS. Analyzed the data: DDS QL JKL NV AHL DNL SS. Contributed reagents/materials/analysis tools: DDS JKL DRB KLL TTB AJI AHL DNL SS. Wrote the paper: DDS SS.

References

- Perry A (2010) Practical surgical neuropathology: a diagnostic approach. Philadelphia: Churchill Livingstone/Elsevier. 620 p.
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2007) World Health Organization Histological Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer. 309 p.
- Ironside J (2002) Diagnostic pathology of nervous system tumours. London; New York: Churchill Livingstone. 651 p.
- Fletcher C (2007) Diagnostic histopathology of tumors. Edinburgh: Churchill Livingstone. 1833 p.
- Burger P (2002) Surgical pathology of the nervous system and its coverings. New York: Churchill Livingstone. 657 p.
- Giannini C, Scheithauer BW (1997) Classification and grading of low-grade astrocytic tumors in children. Brain Pathol 7: 785–798.
- Giannini C, Scheithauer BW, Burger PC, Brat DJ, Wollan PC, et al. (1999) Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 85: 2033–2045.
- KepesJJ (1993) Pleomorphic Xanthoastrocytoma: The Birth of a Diagnosis and a Concept. Brain Pathology 3: 269–274.

9. Kepes JJ, Rubinstein LJ, Eng LF (1979) Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. A study of 12 cases. *Cancer* 44: 1839–1852.
10. Chang HT, Latorre JGS, Hahn S, Dubowy R, Schelper RL (2006) Pediatric cerebellar pleomorphic xanthoastrocytoma with anaplastic features: a case of long-term survival after multimodality therapy. *Childs Nerv Syst* 22: 609–613.
11. Rao AAN, Laack NN, Giannini C, Wetmore C (2010) Pleomorphic xanthoastrocytoma in children and adolescents. *Pediatr Blood Cancer* 55: 290–294.
12. Kros JM, Vecht CJ, Stefanko SZ (1991) The pleomorphic xanthoastrocytoma and its differential diagnosis: a study of five cases. *Hum Pathol* 22: 1128–1135.
13. Pahapill PA, Ramsay DA, Del Maestro RF (1996) Pleomorphic xanthoastrocytoma: case report and analysis of the literature concerning the efficacy of resection and the significance of necrosis. *Neurosurgery* 38: 822–828.
14. Koga T, Morita A, Maruyama K, Tanaka M, Ino Y, et al. (2009) Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. *Neuro-oncology* 11: 446–451.
15. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, et al. (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2: 146–158.
16. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, et al. (2009) Profiling critical cancer gene mutations in clinical tumor samples. *PLoS ONE* 4: e7887.
17. Lurkin I, Stoehr R, Hurst CD, van Tilborg AAG, Knowles MA, et al. (2010) Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. *PLoS ONE* 5: e8802.
18. Kaulich K, Blaschke B, Nümann A, von Deimling A, Wiestler OD, et al. (2002) Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. *J Neuropathol Exp Neurol* 61: 1092–1099.
19. Paulus W, Lisle DK, Tonn JC, Wolf HK, Roggendorf W, et al. (1996) Molecular genetic alterations in pleomorphic xanthoastrocytoma. *Acta Neuropathol* 91: 293–297.
20. Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD (2001) Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. *Neurogenetics* 3: 159–162.
21. Munoz EL, Eberhard DA, Lopes MBS, Schnieder BF, Gonzalez-Fernandez F, et al. (1996) Proliferative activity and p53 mutation as prognostic indicators in pleomorphic xanthoastrocytoma. A clinicopathologic study of six cases. *J Neuropathol Exp Neurol* 55: 606.
22. Weber RG, Hoischen A, Ehrler M, Zipper P, Kaulich K, et al. (2007) Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas. *Oncogene* 26: 1088–1097.
23. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, et al. (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathol* 121. Available: <http://www.ncbi.nlm.nih.gov/pubmed/21274720>.
24. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 360: 765–773.
25. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. *Science* 321: 1807–1812.
26. The Cancer Genome Atlas (TCGA) Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 455: 1061–1068.
27. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, et al. (2005) Mutation analysis of B-RAF gene in human gliomas. *Acta Neuropathol* 109: 207–210.
28. Knobbe CB, Reifenberger J, Reifenberger G (2004) Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. *Acta Neuropathol* 108: 467–470.
29. Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, et al. (2009) RAF expression in human astrocytic tumors. *Int J Mol Med* 23: 17–31.
30. Peraud A, Watanabe K, Schwachheimer K, Yonekawa Y, Kleihues P, et al. (1999) Genetic profile of the giant cell glioblastoma. *Lab Invest* 79: 123–129.
31. Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Boström J, et al. (1997) Molecular genetic analysis of giant cell glioblastomas. *Am J Pathol* 151: 853–857.
32. Peraud A, Watanabe K, Plate KH, Yonekawa Y, et al. (1997) p53 mutations versus EGF receptor expression in giant cell glioblastomas. *J Neuropathol Exp Neurol* 56: 1236–1241.
33. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Ichimura K, et al. (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. *Oncogene* 28: 2119–2123.
34. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, et al. (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res* 68: 8673–8677.
35. Pfister S, Janzarik WG, Renke M, Ernst A, Werft W, et al. (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. *J Clin Invest* 118: 1739–1749.
36. Sievert AJ, Jackson EM, Gai X, Hakonarson H, Judkins AR, et al. (2009) Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. *Brain Pathol* 19: 449–458.
37. Horbinski C, Miller CR, Perry A (2011) Gone FISHing: Clinical Lessons Learned in Brain Tumor Molecular Diagnostics over the Last Decade. *Brain Pathol* 21: 57–73.
38. Von Deimling A, Korshunov A, Hartmann C (2011) The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. *Brain Pathol* 21: 74–87.
39. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, et al. (2010) Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. *Neuro Oncol* 12. Available: <http://www.ncbi.nlm.nih.gov/pubmed/20156809>.
40. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MC, et al. (2010) Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. *Cancer Res* 70: 512–519.
41. Forshew T, Tatevossian RG, Lawson ARJ, Ma J, Neale G, et al. (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. *J Pathol* 218: 172–181.
42. Murray JC, Donahue DJ, Malik SI, Dzurik YB, Braly EZ, et al. (2010) Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome. *J Neurooncol*. Available: <http://www.ncbi.nlm.nih.gov/pubmed/20730472>.
43. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. *Nature* 417: 949–954.
44. Bals J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 116: 597–602.
45. Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, et al. (2010) Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. *Acta Neuropathol* 119: 509–511.
46. Kepes JJ, Kepes M, Slowik F (1973) Fibrous xanthomas and xanthosarcomas of the meninges and the brain. *Acta Neuropathol* 23: 187–199.
47. Perry A, Giannini C, Scheithauer BW, Rojiani AM, Yachnis AT, et al. (1997) Composite pleomorphic xanthoastrocytoma and ganglioglioma: report of four cases and review of the literature. *Am J Surg Pathol* 21: 763–771.
48. Sugita Y, Irie K, Ohshima K, Hitosumatsu T, Sato O, et al. (2009) Pleomorphic xanthoastrocytoma as a component of a temporal lobe cystic ganglioglioma: a case report. *Brain Tumor Pathol* 26: 31–36.
49. Kim Y, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, et al. (2010) Molecular classification of low-grade diffuse gliomas. *Am J Pathol* 177: 2708–2714.
50. Flaherty KT (2010) Narrative review: BRAF opens the door for therapeutic advances in melanoma. *Ann Intern Med* 153: 587–591.
51. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, et al. (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. *Cancer Res* 65: 10686–10691.
52. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, et al. (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. *Proc Natl Acad Sci U S A* 103: 57–62.
53. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature* 467: 596–599.
54. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 363: 809–819.
55. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, et al. (2010) The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. *Proc Natl Acad Sci U S A* 107: 14903–14908.
56. Cartmill M, Hewitt M, Walker D, Lowe J, Jaspán T, et al. (2001) The use of chemotherapy to facilitate surgical resection in pleomorphic xanthoastrocytoma: experience in a single case. *Childs Nerv Syst* 17: 563–566.